Development Of Novel Reagents For The Point-of-care(field) Diagnosis &differentiation Of The Malaria Parasites, Plasmodi
Funder
National Health and Medical Research Council
Funding Amount
$117,000.00
Summary
Malaria is a major global health problem. 500 million people become infected with malaria parasites every year and 2-3 million people die each year from the disease. Rapid diagnosis of the disease is needed to allow correct treatment protocols. Increasingly protein-based immunochromatographic tests are being employed for the diagnosis of malaria as they offer significant advantages over classical thick smear tests, which require trained personnel and laboratory facilities. We propose to develop ....Malaria is a major global health problem. 500 million people become infected with malaria parasites every year and 2-3 million people die each year from the disease. Rapid diagnosis of the disease is needed to allow correct treatment protocols. Increasingly protein-based immunochromatographic tests are being employed for the diagnosis of malaria as they offer significant advantages over classical thick smear tests, which require trained personnel and laboratory facilities. We propose to develop a protein-based malaria diagnostic that has the ability to distinguish the two major human pathogens, P.falciparum and P. vivax.Read moreRead less
Antibodies are the main line of defence the immune system utilises to target viruses and bacteria that invade our body. Raising the level of antibodies can therefore offer effective protection against disease. However, as antibodies cannot be taken orally (as a tablet) they have to be injected into the blood stream. We aim to overcome this limitation by generating antibodies that survive the passage through the stomach, allowing us to target conditions such as Crohn's disease.
Afinity Maturation And Development Of An Anti-inflammatory Monoclonal Antibody
Funder
National Health and Medical Research Council
Funding Amount
$387,489.00
Summary
Antibodies are a relatively new class of drugs that directly target molecular mechanisms of disease. Antibody therapies, such as the breast cancer drug Herceptin, have significantly increased our arsenal of effective therapeutics. In collaboration with G2 Therapies, we will use cutting-edge genetic engineering technology to produce fully human antibodies for the treatment of inflammatory diseases, such as rheumatoid arthritis.
EphA2 And EphA3 Maintain Tumour Initiating Cells And Are Therapeutic Targets In Brain Cancer
Funder
National Health and Medical Research Council
Funding Amount
$612,860.00
Summary
High-grade glioma (HGG) is the most common adult brain cancer; current treatments have increased survival times by months only. Our studies have shown brain cancer specific expression of a family of cell surface proteins called Eph receptors. Furthermore we have shown targeting these receptors with Eph antibodies leads to a significant reduction in brain cancer tumour growth. We now propose to test targeting these receptors in combination to achieve greater responses with minimal side effects.